353 related articles for article (PubMed ID: 25906633)
1. The efficacy of bevacizumab in diabetic macular oedema in a 12-month follow-up.
Jamrozy-Witkowska A; Grabska-Liberek I; Skonieczna K
Klin Oczna; 2014; 116(4):237-41. PubMed ID: 25906633
[TBL] [Abstract][Full Text] [Related]
2. Intravitreal bevacizumab (Avastin) therapy for persistent diffuse diabetic macular edema.
Haritoglou C; Kook D; Neubauer A; Wolf A; Priglinger S; Strauss R; Gandorfer A; Ulbig M; Kampik A
Retina; 2006; 26(9):999-1005. PubMed ID: 17151486
[TBL] [Abstract][Full Text] [Related]
3. Long-term effect of intravitreal bevacizumab (avastin) in patients with chronic diffuse diabetic macular edema.
Kook D; Wolf A; Kreutzer T; Neubauer A; Strauss R; Ulbig M; Kampik A; Haritoglou C
Retina; 2008 Oct; 28(8):1053-60. PubMed ID: 18779710
[TBL] [Abstract][Full Text] [Related]
4. Bevacizumab intravitreal injections in the treatment of diabetic macular oedema.
Małgorzata W; Diana D; Agnieszka B; Zofia M
Klin Oczna; 2013; 115(1):15-9. PubMed ID: 23882733
[TBL] [Abstract][Full Text] [Related]
5. Prospective study of intravitreal triamcinolone acetonide versus bevacizumab for macular edema secondary to central retinal vein occlusion.
Ding X; Li J; Hu X; Yu S; Pan J; Tang S
Retina; 2011 May; 31(5):838-45. PubMed ID: 21293319
[TBL] [Abstract][Full Text] [Related]
6. Primary intravitreal bevacizumab (Avastin) for diabetic macular edema: results from the Pan-American Collaborative Retina Study Group at 6-month follow-up.
Arevalo JF; Fromow-Guerra J; Quiroz-Mercado H; Sanchez JG; Wu L; Maia M; Berrocal MH; Solis-Vivanco A; Farah ME;
Ophthalmology; 2007 Apr; 114(4):743-50. PubMed ID: 17398322
[TBL] [Abstract][Full Text] [Related]
7. Intravitreal bevacizumab and/or macular photocoagulation as a primary treatment for diffuse diabetic macular edema.
Solaiman KA; Diab MM; Abo-Elenin M
Retina; 2010; 30(10):1638-45. PubMed ID: 20838357
[TBL] [Abstract][Full Text] [Related]
8. Comparison of intravitreal bevacizumab and ranibizumab treatment for diabetic macular edema.
Ozturk BT; Kerimoglu H; Bozkurt B; Okudan S
J Ocul Pharmacol Ther; 2011 Aug; 27(4):373-7. PubMed ID: 21631366
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of one intravitreal injection of bevacizumab in diabetic macular oedema.
Fang X; Sakaguchi H; Gomi F; Oshima Y; Sawa M; Tsujikawa M; Ikuno Y; Kamei M; Kusaka S; Tano Y
Acta Ophthalmol; 2008 Nov; 86(7):800-5. PubMed ID: 18547274
[TBL] [Abstract][Full Text] [Related]
10. Intravitreal triamcinolone versus bevacizumab for treatment of refractory diabetic macular oedema (IBEME study).
Paccola L; Costa RA; Folgosa MS; Barbosa JC; Scott IU; Jorge R
Br J Ophthalmol; 2008 Jan; 92(1):76-80. PubMed ID: 17965109
[TBL] [Abstract][Full Text] [Related]
11. Short-term safety and efficacy of intravitreal bevacizumab for pseudophakic cystoid macular edema.
Barone A; Russo V; Prascina F; Delle Noci N
Retina; 2009 Jan; 29(1):33-7. PubMed ID: 18854783
[TBL] [Abstract][Full Text] [Related]
12. Repeated intravitreal bevacizumab injection with and without macular grid photocoagulation for treatment of diffuse diabetic macular edema.
Solaiman KA; Diab MM; Dabour SA
Retina; 2013 Sep; 33(8):1623-9. PubMed ID: 23538584
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of 1.25 MG versus 2.5 MG intravitreal bevacizumab for diabetic macular edema: six-month results of a randomized controlled trial.
Lam DS; Lai TY; Lee VY; Chan CK; Liu DT; Mohamed S; Li CL
Retina; 2009 Mar; 29(3):292-9. PubMed ID: 19287286
[TBL] [Abstract][Full Text] [Related]
14. Intravitreal bevacizumab (Avastin) for primary treatment of diabetic macular oedema.
Ozkiriş A
Eye (Lond); 2009 Mar; 23(3):616-20. PubMed ID: 18437176
[TBL] [Abstract][Full Text] [Related]
15. Comparing intravitreal triamcinolone acetonide and bevacizumab injections for the treatment of diabetic macular oedema: a randomized double-blind study.
Isaac DL; Abud MB; Frantz KA; Rassi AR; Avila M
Acta Ophthalmol; 2012 Feb; 90(1):56-60. PubMed ID: 20015098
[TBL] [Abstract][Full Text] [Related]
16. Phacoemulsification with intravitreal bevacizumab and triamcinolone acetonide injection in diabetic patients with clinically significant macular edema and cataract.
Akinci A; Muftuoglu O; Altınsoy A; Ozkılıc E
Retina; 2011 Apr; 31(4):755-8. PubMed ID: 21124251
[TBL] [Abstract][Full Text] [Related]
17. Primary intravitreal bevacizumab for diffuse diabetic macular edema: the Pan-American Collaborative Retina Study Group at 24 months.
Arevalo JF; Sanchez JG; Wu L; Maia M; Alezzandrini AA; Brito M; Bonafonte S; Lujan S; Diaz-Llopis M; Restrepo N; Rodríguez FJ; Udaondo-Mirete P;
Ophthalmology; 2009 Aug; 116(8):1488-97, 1497.e1. PubMed ID: 19545900
[TBL] [Abstract][Full Text] [Related]
18. Functional and anatomic response of the retina and the choroid to intravitreal bevacizumab for macular edema.
Forte R; Cennamo G; Breve MA; Vecchio EC; de Crecchio G
J Ocul Pharmacol Ther; 2012 Feb; 28(1):69-75. PubMed ID: 22059904
[TBL] [Abstract][Full Text] [Related]
19. Optical coherence tomography and vessel diameter changes after intravitreal bevacizumab in diabetic macular oedema.
Soliman W; Vinten M; Sander B; Soliman KA; Yehya S; Rahman MS; Larsen M
Acta Ophthalmol; 2008 Jun; 86(4):365-71. PubMed ID: 18028237
[TBL] [Abstract][Full Text] [Related]
20. Treatment of anti-vascular endothelial growth factor-resistant diabetic macular edema with dexamethasone intravitreal implant.
Lazic R; Lukic M; Boras I; Draca N; Vlasic M; Gabric N; Tomic Z
Retina; 2014 Apr; 34(4):719-24. PubMed ID: 23975006
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
